Blog

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors

Photo taken from acgtfoundation.org

Aug 6, 2024, 10:23

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors

Journal for ImmunoTherapy of Cancer made the following post on X:

“New JITC article: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).”

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Authors: Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, Justin Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E. Sanborn, Jaspreet S. Grewal, Ajita Narayan, Amita Patnaik, Justin F. Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J. Chisamore, Stanford L. Peng, Allison Naumovski.

Source: Journal for ImmunoTherapy of Cancer/X

Ajita Narayan Allison Naumovski Amanda Enstrom Amita Patnaik cancer Diwakar Davar Heather Thomas Heidi LeBlanc Jaspreet S. Grewal Justin F. Gainor Justin Moser Lori Blanchfield Ludimila Cavalcante Mario Sznol Mark Voskoboynik Meredith McKean Michael J. Chisamore Michael Millward Nehal Lakhani OncoDaily Oncology Rachel E. Sanborn Stanford L. Peng

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer